Introduction {#s1}
============

Rheumatoid arthritis (RA) is the most common, chronic, autoimmune disease with world prevalence of 0.5--1% of the population (Woolf and Pfleger, [@B26]). In central and Eastern Europe prevalence estimates are: 0.37% for Hungary among people aged 14--65, for the Czech Republic 0.61%, Estonia 0.46%, and out of them 50--55% of the people are in productive ages (Kiss et al., [@B15]). In Romania the prevalence is 0.2% among males and 0.5% among females, in Russia around 0.68% (Orlewska et al., [@B21]). For Bulgaria in 2008 registered patients with RA numbered 29 711 (0.4%) (Kobelt and Kasteng, [@B16]).

RA affects mortality and quality of life of patients (Blumenauer et al., [@B2]; Haroon et al., [@B12]). The average life expectancy is 4 years lower for males with RA and 10 years for females than their respective averages. In patients with severely affected mobility, acute form of RA, visceral manifestation, and concomitant diseases the mortality rate is higher (Kvien, [@B17]).

Biological medicines are considered as a cornerstone therapy of rheumatoid arthritis (RA) for patients that do not respond to methotrexate or other disease modifying agents (Felson et al., [@B8], [@B9]). Biologicals change the course of the disease, improve the quality of life of the patients, and decrease mortality (Felson et al., [@B10]).

The term biologic medicines include adalimumab, certolizumab pegol, etanercept, golimumab, infliximab which belong to TNF alfa inhibitors class, as well as medicines acting through different mechanism such as abatacept, anakinra, rituximab, and tocilizumab. All are recognized as an effective treatment for RA, but they are usually recommended only for patients with insufficient response or intolerance to synthetic disease modifying agents, due to price concerns by authorities (Nam et al., [@B20], [@B19]; Aaltonen et al., [@B3]; Smolen et al., [@B24]).

There are numerous studies of the cost-effectiveness of biologic therapy but real life studies are limited (Cooper, [@B5]; Joensuu et al., [@B13]). There is also no study comparing the quality of life of and cost of RA therapy in Bulgaria in real life settings. The gap in knowledge provoked our interest toward this research. Therefore the aim of this study is to analyse the cost and quality of life of patients with RA threated with biological medicines in Bulgaria.

Materials and methods {#s2}
=====================

This is an observational, real-life study of 124 patients treated with biological medicines during 2012--2016 at the University hospital "St. Ivan Riskli" in Sofia, specialized in rheumatology disease therapy.

Patients were consecutively recruited after their transfer from non-biological to biological therapy and followed for 1 year.

Inclusion criteria were: age above 18 years; willingness to participate after informed consent; confirmed diagnosis of RA according ACR/EULAR (2010) (Aletaha et al., [@B4]); treatment naïve on biological therapy; previous treatment with methotrexate and non-steroidal anti-inflammatory drugs or methotrexate and other disease modifying therapy; adherence to therapy in the previous 6 months and during the whole period of observation. Exclusion criteria were infectious diseases (HIV, tuberculosis); cardiac insufficiency (NYHA III and IV grade); malignant hypertension; psychiatric diseases; any neoplasms or proliferative lymph diseases within the previous 5 years (Dolgin et al., [@B7]); alcohol or narcotic abuse; deficiencies in recognition abilities. On total 110 female and 14 male were recruited.

The quality of life was assessed through the EQ5D questionnaire (Devlin, [@B6]). Both section of EQ5D were used -- VAS and EQ5D questionnaire. The measurements of the quality of life (QoL) were performed at the beginning of the therapy, after 6 months, and after 1 year. Then the changes in the QoL were evaluated statistically.

Physicians choose the biological medicines according to their personal opinion based on corresponding clinical status of the patients and available medicines in the reimbursement list. On the basis of physicians\' choice, the patients were separated in groups of prescribed biologic products for the purposes of the analysis. The following groups were formed: tocilizumab (*n* = 30), cetrolizmab (*n* = 16), golimumab (*n* = 22), etanercept (*n* = 20), adalimumab (*n* = 20), rituximab (*n* = 16). The changes in QoL were compared among groups of patients for both scales VAS and EQ5D questionnaire.

Ethical committee of the University hospital "St. Ivan Riskli" in Sofia approved the study.

The yearly pharmacotherapy cost for the corresponding medicine was calculated by multiplying the official price per defined daily dose gathered from National council on prices and reimbursement by 365 days[^1^](#fn0001){ref-type="fn"}. The prices were collected at the end of 2016 and expressed in national currency (BGN). The exchange rate is 1 Euro = 1.958 BGN.

To evaluate the cost effectiveness of the products we built a decision tree model with TreeAgePro software comparing the yearly pharmacotherapy cost with the changes in EQ5D scores after 1 year of therapy. Probability of prescribing a particular INN was derived from our sample.

Results {#s3}
=======

Changes in the quality of life (QoL)
------------------------------------

Statistically significant QoL increases were observed for both EQ5D scales (Table [1](#T1){ref-type="table"}). Patients\' self-assessment of their health state using the visual analogs scale (VAS) grew from 44 to 76 point out of 100 maximum possible. Similar increases were observed in the combined EQ5D evaluation---from 0.42 to 0.624 points.

###### 

Changes in the QoL during the observation for all patients.

  **Scale**                                        **Beginning of therapy**   **After 6 months**        **After 1 year**          ***P***
  ------------------------------------------------ -------------------------- ------------------------- ------------------------- -----------
  Visual analog scale(VAS) - Mean Value (95% CI)   44.056 (41.220--46.893)    63.242 (60.306--66.178)   76.379 (73.739--79.019)   \<0.00001
  EQ5D- Mean Value (95% CI)                        0.420 (0.386 to 0.455)     0.5896 (0.216 to 0.643)   0.624 (0.595 to 0.653)    \<0.0001

Overall, self-evaluation by VAS per INN increased significantly but none of the measurements revealed statistically significant differences when comparing different INNs with each other. Therefore, none of the changes in the QoL per INN are significant (Table [2](#T2){ref-type="table"}).

###### 

VAS scores for different INNs.

  **INN**                    **VAS median value beginning of therapy**   **VAS median value after 6 months therapy**   **VAS median value after 1 year therapy**
  -------------------------- ------------------------------------------- --------------------------------------------- -------------------------------------------
  Adalimumab                 40.00                                       66.50                                         80.00
  cetrolizumab-pegol         43.50                                       57.00                                         77.50
  Etanercept                 43.50                                       65.00                                         75.00
  Golimumab                  42.50                                       69.00                                         80.50
  Rituximab                  50.00                                       69.50                                         82.50
  Tocilizumab                41.50                                       69.50                                         85.00
  Kruskal-Wallis test -- p   0.782038                                    0.670970                                      0.670249

Similar were the results for EQ5D domains where there was no difference among the scores between the medicines (Table [3](#T3){ref-type="table"}). For adalimumab and cetrolizumab, no changes in the EQ5D score were observed after second and third measurement.

###### 

EQ5D scores for different INNs.

  **INN**                   **EQ5D median value beginning of therapy**   **EQ5D median valueafter 6 months therapy**   **EQ5D median value after 1 year therapy**
  ------------------------- -------------------------------------------- --------------------------------------------- --------------------------------------------
  Adalimumab                0.480                                        0.560                                         0.560
  cetrolizumab-pegol        0.241                                        0.570                                         0.570
  Etanercept                0.480                                        0.570                                         0.620
  Golimumab                 0.480                                        0.586                                         0.630
  Rituximab                 0.480                                        0.598                                         0.660
  Tocilizumab               0.480                                        0.570                                         0.670
  Kruskal-Wallis test - p   0.526611                                     0.715242                                      0.318079

Male patients reported lower QoL than female patients (Table [4](#T4){ref-type="table"}) although for both groups the VAS and EQ5D scale showed a statistically significant increase in their scores.

###### 

Differences in QoL between male and female group.

  **Scale**                                        **Beginning of therapy**   **After 6 months**        **After 1 year**           ***P***
  ------------------------------------------------ -------------------------- ------------------------- -------------------------- -----------
  **FEMALE GROUP**                                                                                                                 
  Visual analog scale(VAS) - median (min to max)   45.000 (10.00--80.00)      68.000 (5.00--100.000)    80.000 (30.000--100.000)   \<0.00001
  EQ5D- Mean Value (95% CI)                        0.425 (0.389--0.461)       0.589 (0.559--0.619       0.622 (0.591--0.652)       \<0.0001
  **MALE GROUP**                                                                                                                   
  Visual analog scale(VAS) - median (min to max)   33.50 (10.000--75.000)     57.000 (30.000--85.000)   79.000 (46.000--100.000)   \<0.00001
  EQ5D- Mean Value (95% CI)                        0.387 (0.260 to 0.514)     0.5935 (0.48--0.650)      0.640 (0.530--0.750)       \<0.0001

Cost-effectiveness analysis
---------------------------

Due to the lack of statistical significance in the EQ5D scores between the prescribed INNs we consider the therapeutic results achieved as identical. Therefore we constructed a decision tree model where the choice of biologic therapy depends only on the subjective physician opinion and he/she could choose any one of the available on the local market alternatives (Figure [1](#F1){ref-type="fig"}). The probability of prescribing a particular INN is derived from our patient sample.

![The decision tree model.](fphar-09-00794-g0001){#F1}

The yearly cost of therapy with a particular biological is calculated for every INN and the lowest is with rituximab (Table [5](#T5){ref-type="table"}). EQ5D scores at the end of therapy are measures of effectiveness.

###### 

Results of the cost-effectiveness calculation.

                 **Cost**    **Incremental cost**   **Effectiveness**   **Incremental effectiveness**   **CER[^\*^](#TN1){ref-type="table-fn"}/ICER[^\*\*^](#TN2){ref-type="table-fn"}**
  -------------- ----------- ---------------------- ------------------- ------------------------------- ----------------------------------------------------------------------------------
  Cetrolizumab   20910,85    20910,85               0.56                0.56                            3,734,080
  Adalimumab     24119,20    3208,35                0.57                0.01                            32,083,500
  Etanercept     22078,85    −2040,35               0.62                0.05                            −4,080,700
  Tocilizimab    25878,50    3799,65                0.63                0.01                            37,996,500
  Rituximab      9937,88     −15940,62              0.66                0.03                            −53,135,400
  Golimumab      23812,60    13874,72               0.67                0.01                            138,747,200
                 **Cost**    **Incremental cost**   **Effectiveness**   **Incremental effectiveness**   **CER/ICER**
  Adalimumab     24,119,20   241,192                0.57                0.57                            4,231,439
  Etanercept     2,207,885   −204,035               0.62                0.05                            −4,080,700
  Tocilizimab    2,587,850   379,965                0.63                0.01                            37,996,500
  Rituximab      993,788     −1,594,062             0.66                0.03                            −53,135,400
                 **Cost**    **Incremental cost**   **Effectiveness**   **Incremental effectiveness**   **CER/ICER**
  Etanercept     2,207,885   2,207,885              0.62                0.62                            3561,105
  Rituximab      993,788     −1,214,097             0.66                0.04                            −30,352,425

CER (cost-effectiveness ration = cost of INN/effectiveness of INN). Used only for the first alternative.

*ICER (Incremental cost---effectiveness ration = (Cost~a~−Cost~b~)/(Effectiveness~a~−Effectiveness~b~). For every INN is calculated the difference between the cost and effectiveness with the previous one INN in the table*.

Applying the rules for incremental cost effectiveness ratio calculation (ICER) rituximab appears to be the most cost-effective alternative, followed by etanercept, tocilizumab, and adalimumab. Cetrolizumab is less effective and golimumab is not cost-effective (Table [5](#T5){ref-type="table"}) despite its higher effectiveness.

Cetrolizumab, adalimumab, golimumab, and tocilizumab are all dominated by rituximab. The cost-effectiveness of biological therapy varies from 30 to 66 thousand BGN for unit of improvement in the EQ5D after one year of therapy. If the willingness to pay threshold is 30 000 only for rituximab the ICER is below that threshold (Figure [2](#F2){ref-type="fig"}).

![Cost effectiveness plate for biological medicines.](fphar-09-00794-g0002){#F2}

Discussion {#s4}
==========

Improvement in the quality of life of individual patients with RA is one of the main goals of therapy because of its serious rate of deterioration (Jørgensen et al., [@B1]). Our study confirms that the QoL measured with EQ5D improves quickly in the beginning of therapy and subsequently slows down toward the end of one year of therapy. Despite this, overall improvement is statistically significant. Similar results were reported in other articles although in our study we observed slightly higher EQ5D scores (Pollard et al., [@B23]; Pickard et al., [@B22]; Aaltonen et al., [@B3]; Kim et al., [@B14]).

EQ-5D was chosen as utility outcome because of its simplicity, wide-spread use and well-established scores. To the best of our knowledge this is the first national study of the QoL of patients with RA that uses the EQ5D.

Our study also shows that males reported lower quality of life than females. It could be due to different perception between genders toward pain and suffering (Wijnhoven et al., [@B25]). A reason for lower values could also be the small male sample. Many studies report that RA affects mostly women, which was confirmed in our study results for Bulgaria (Woolf and Pfleger, [@B26]; Kiss et al., [@B15]).

We found no differences in the changes of the QoL with different INNs of biological medicines after one year therapy. Similar results were reported in a systematic review and meta-analysis, published in 2011 (Malottki et al., [@B18]). This could be because real-life settings influence the results when measuring, which could account for the disparity when compared to results published from randomized clinical trials (Gülfe et al., [@B11]). The lack of statistically significant differences allows building a decision tree model that reflects real life therapy, based on the probability for an individual physician\'s choice. Other studies have also selected rituximab as a cost-effective alternative (Pollard et al., [@B23]; Joensuu et al., [@B13]). In general treatment of rheumatoid arthritis with biologicals improves quality of life significantly. Only rituximab was cost-effective. These results could be used by health authorities to optimize RA therapy and better control prescription of biologics.

The limitations are the overall low number of participants, especially the number of male patients, as well as the number in each different biological group. It is also a single center study. The strengths are the quality of the data.

Further analysis should be done when new biosimilars appear on the market and medicines prices change.

Conclusions {#s5}
===========

Therapy with biological medicines improves statistically significant the quality of life of patients, measured through VAS and EQ5D scales. Despite the improvement in the quality of life all biological medicines appear not to be cost-effective due to their high incremental cost-effectiveness ratio (ICER). Rituximab\'s incremental ratio (ICER) falls closer to the three times gross domestic product per capita threshold and should be considered as a preferred alternative for RA therapy. In general we can conclude that the treatment of rheumatoid arthritis with biologicals improves quality of life significantly. Only rituximab was cost-effective.
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